[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"osteopenia-or-osteoporosis\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:osteopenia-or-osteoporosis":29},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,43],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":17,"sex":18,"minAge":19,"maxAge":20,"enrollmentInfo":21,"targetDuration":4,"studyType":24,"phases":25,"briefSummary":27,"conditions":28,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":31,"lastUpdatePostDateStruct":32,"startDateStruct":35,"completionDateStruct":37,"leadSponsor":39,"locationsCount":42},"100499788","profylactic-treatment-for-patients-in-risk-osteoporosis-100499788",false,"NCT05787808","Profylactic Treatment for Patients in Risk Osteoporosis","The Effect on Bone Marker and Body Mineral Density (BMD) of Daily Jarlsberg Cheese Intake in Risk Patient for Osteoporosis","PF-Jarlsberg","Inclusion Criteria:\n\n* Osteopeni patients (OP) of both genders above 55 years of age. OPs are defined as patients with T-score below 0.0 but larger than -2.5.\n\nExclusion Criteria:\n\n* • Eating disorder\n\n  * Known gastrointestinal disorder.\n  * Abnormal liver or kidney function.\n  * Diabetes mellitus type I.\n  * Diabetes type II without sufficient control.\n  * Suffering from verified cancer.\n  * Under systemic treatment with corticosteroids or other immunosuppressive drugs the last 3 weeks before start of the trial treatment.\n  * Under active antiresorptive treatment or anabolic treatment.\n  * Participating in another clinical trial with pharmaceuticals the last six weeks before start of this trial treatment.\n  * Known milk product allergy.\n  * Not able to understand information.\n  * Do not want or not able to give written consent to participate in the study.",true,"ALL","55 Years","85 Years",{"count":22,"type":23},60,"ESTIMATED","INTERVENTIONAL",[26],"NA","The aim is to compare the daily intake of Calsium (Ca) + vitamin D with and without daily optimal efficacy dose (OED) of Jarlsberg on Bone Mineral Density (BMD) and bone markers (BM) to Osteopeni patients (OP).\n\n* The study population consists of OP-patients of post-menopausal women and men above 55 years of age. OP patients are defined as patients with a T-score below 0.0, but larger than -2.5.\n* The study will be performed as a randomized, single-blinded Norwegian multicentre trial with stratified semi-cross-over design with gender and site as stratification factors. The OP-patients included in the study will be allocated to one of the two treatment groups by block randomization with random block size between 2 and 6.\n* Women in post-menopausal age have a daily OED Jarlsberg of 45 gram and men in the same age interval have a daily OED of 55 gram.\n* The main response variable will be the change in Bone Mineral Density (BMD),total Osteocalcin (tOC) and different bone markers (BM).\n* Participants, who fulfil the inclusion criteria, do not meet any of the exclusion criteria and willing to give informed consent to participate will be included and receiving 40µg vitamin D and 500 mg Ca tablets per day, but asked not to eat Jarlsberg cheese the following week. During this week demographic data, bloodsampling for measurement of Osteocalcin and BM and diet registration will be performed.In the clinical study, all the included patients will continue with Ca+ vitamin D, but half of the patient will additionally receive daily OED of Jarlsberg cheese. After 16 weeks, all the patients will receive both Ca+vitamin D and OED of Jarlsberg for addionally 16 weeks. The total duration of the study will be 32 weeks for the patients initially allocated to Jarlsberg and 48 weeks for those allocated only to Ca+vitamin D. The patients will be investigated initially and every 16 weeks.\n* A total of 30 patients will be included in each of the two groups.",[29],"Osteopenia or Osteoporosis","RECRUITING","2025-09-23",{"date":33,"type":34},"2025-09-29","ACTUAL",{"date":36,"type":34},"2023-05-02",{"date":38,"type":23},"2025-10-20",{"name":40,"class":41},"Meddoc","OTHER",1,{"id":44,"slug":45,"hasResults":11,"nctId":46,"briefTitle":47,"officialTitle":48,"acronym":4,"eligibilityCriteria":49,"healthyVolunteers":17,"sex":50,"minAge":51,"maxAge":52,"enrollmentInfo":53,"targetDuration":4,"studyType":24,"phases":55,"briefSummary":56,"conditions":57,"keywords":4,"overallStatus":58,"whyStopped":4,"lastUpdateSubmitDate":59,"lastUpdatePostDateStruct":60,"startDateStruct":62,"completionDateStruct":64,"leadSponsor":66,"locationsCount":4},"100558388","the-effect-of-pre-exercise-feeding-on-bone-turnover-biomarkers-100558388","NCT06550466","The Effect of Pre-exercise Feeding on Bone Turnover Biomarkers","The Influence of Pre-exercise Feeding on Acute Bone Turnover Biomarkers in Response to Physical Activity in Healthy Participants","Inclusion Criteria:\n\n* Male (females excluded to remove the interplay between menstrual cycle and bone turnover)\n* Caucasian ethnicity\n* Aged 28 ± 4 years\n* Are physically active (meet the UK guidelines for physical activity of at least 150 minutes moderate intensity activity and\u002For at least 75 minutes of vigorous intensity activity per week)\n* Otherwise, healthy, able and willing to participate and provide written informed consent\n\nExclusion Criteria:\n\n* Current smokers\n* Excessive alcohol consumption (max 15 alcohol units\u002Fweek)\n* Any musculoskeletal injury\u002Fdisabilities\n* Any conditions known to affect bone metabolism (e.g. uncontrolled hyper-\u002Fhypothyroidism, hyperparathyroidism, hypo-\u002Fhypercalcaemia) or malabsorption syndromes (e.g. Crohn's disease, coeliac disease or inflammatory bowel disease).\n* Taking any medication known to affect bone metabolism (such as glucocorticoids or bisphosphonates)\n* Positive Covid-19 test within the last 8 weeks\n* Suffered a fracture in the previous 12 months\n* Sedentary status (see physical activity inclusion criteria above)\n* Have been told by medical professionals that they should not take part in moderate to high intensity exercise\n* Should not be a professional athlete or take part in significant competitive recreational activity (takes no more than 4 structured exercise sessions per week on average)\n* History of diagnosed eating disorders","MALE","24 Years","32 Years",{"count":54,"type":23},16,[26],"Osteoporosis is a major contributor to loss of independence due to bone fractures and resulting hospital treatments lead to significant morbidity. While pharmacological treatments can reduce consequences of osteoporosis, there is a pressing need for non-pharmacological interventions to improve bone health across the life-course and to reduce likelihood of age-related bone disease.\n\nThis study will allow us to determine whether synergistic potentiating effects on bone metabolism are observed in humans in relation to the timing of food ingestion and what recommendations can be made to people with respect to food ingestion and exercise to obtain the maximal bone benefits from aerobic exercise. Furthermore, if we can identify interventions that potentiate bone's response to aerobic exercise in younger adults, then such interventions may have the ability to maximise bone mass in younger adults so that with ageing, the additional bone mineral density and improved bone microarchitecture would extend the time before osteoporotic \"fracture thresholds\" are reached. Therefore, understanding the bone metabolic response to exercise following fasting and feeding in younger adults is important.",[29],"NOT_YET_RECRUITING","2024-08-08",{"date":61,"type":34},"2024-08-13",{"date":63,"type":23},"2024-10",{"date":65,"type":23},"2025-06",{"name":67,"class":41},"Sheffield Hallam University"]